Post Reply
161-180 of 409
strong resistance at 340/345...need to clear with volume then breakout to above 40c.. waiting...
Invest1 ( Date: 29-Apr-2022 10:10) Posted:
|
The gate of 1200k is set up at 0.345, wow....continue to buy...funny moves...
if can clear the 340/345 resistance convincely likely indication that BBs will want to push to near target price..
PQTPQK ( Date: 29-Apr-2022 09:31) Posted:
|
Last year my target for the takeover is 45 cents. Now open up 50cent is reasonable, could be higher since the revenue and profit is much higher than expected.
Remember to buy...the deal fail last year, maybe alive again as Singapore opens up for tourist again.
Just follow brokerage target acctually pretty zhun...
any near term target price??
Invest1 ( Date: 29-Apr-2022 09:10) Posted:
|
This is really a good news. I still expecting the takeover deal..
josephyeo ( Date: 29-Apr-2022 01:35) Posted:
|
Wolf Money(portfolio update end April 2022) Long post!
Commentary
Straits Times Index in face of multiple challenges was surprisingly resilient. Index was down marginally in April. Nasdaq was down more than 17% ytd . A bloodbath was lashed out among the tech stocks in April. LWF had a quiet April. Cash yield was at 0.08% per month. I was pretty bearish since March after Fed changed their dovish view on interest rate policy. There is market talk of a bigger 0.75% jump in interest rate in May.😮
https://lonewolfinvestor.blogspot.com/2022/04/wolf-moneyportfolio-update-end-april.html?m=1
Dyodd
Commentary
Straits Times Index in face of multiple challenges was surprisingly resilient. Index was down marginally in April. Nasdaq was down more than 17% ytd . A bloodbath was lashed out among the tech stocks in April. LWF had a quiet April. Cash yield was at 0.08% per month. I was pretty bearish since March after Fed changed their dovish view on interest rate policy. There is market talk of a bigger 0.75% jump in interest rate in May.😮
https://lonewolfinvestor.blogspot.com/2022/04/wolf-moneyportfolio-update-end-april.html?m=1
Dyodd
Singapore Medical Group
2 buy recommendations:
1. Lim & Tan Securites. Date - 28 April 2022
Buy w target of 50.0 cts
2. UOB Kay Hian. Date - 10 March 2022.
Buy w target of 53.0 cts
For info only. Vested
2 buy recommendations:
1. Lim & Tan Securites. Date - 28 April 2022
Buy w target of 50.0 cts
2. UOB Kay Hian. Date - 10 March 2022.
Buy w target of 53.0 cts
For info only. Vested
Keep a lookout for SingMed...possible outbreak soon.
Yes. The profit is pretty decent. Hopefully can declare more dividends.
Singapore MedicalGroup
Share some datas on Revenue/Profits of past 5 years:
From the above, its clear that the company has been showing growth in revenue and profits year after year
except for year 2020,the 1st pandemic year.
Above for info only. Vested. Dyodd.
Share some datas on Revenue/Profits of past 5 years:
| singmedical | FY' 17 | FY' 18 | FY' 19 | FY' 20 | FY' 21 |
| revenue | 68001 | 85,069 | 94,672 | 87,340 | 100,840 |
| net profit | 8499 | 12,928 | 13,661 | 8,730 | 15,608 |
From the above, its clear that the company has been showing growth in revenue and profits year after year
except for year 2020,the 1st pandemic year.
Above for info only. Vested. Dyodd.
Singapore Medical Group.
Buy call from UOBKayHian:
SMG announced a record-high PATMI of S$15.6m (+78.8% yoy), beating expectations.
Recovery in demand for the diagnostic and aesthetics segment drove earnings past
pre-pandemic levels. The reopening of international borders will also help the foreign
patient load to recover, which historically contributed 15-20% of annual revenue.
The group continues to make inroads in overseas growth and is focused on key vertical
acquisitions. Maintain BUY with a higher PE-based target price of S$0.53.
UOBKayHian - 10 March 2022
Buy call from UOBKayHian:
SMG announced a record-high PATMI of S$15.6m (+78.8% yoy), beating expectations.
Recovery in demand for the diagnostic and aesthetics segment drove earnings past
pre-pandemic levels. The reopening of international borders will also help the foreign
patient load to recover, which historically contributed 15-20% of annual revenue.
The group continues to make inroads in overseas growth and is focused on key vertical
acquisitions. Maintain BUY with a higher PE-based target price of S$0.53.
UOBKayHian - 10 March 2022
Singapore Medical Group
Below is a quote taken from Message to Shareholders:
" While we are delighted with the results, this is just the beginning as we continue
to chart growth both in Singapore and overseas as we look to emerge stronger from the pandemic."
As seen from above quote, the company is actually very active in Vietnam, Indonesia and Australia.
Indonesia continued to grow " in revenue and profitability despite the challenging COVID-19 environment." .
In Vietnam, the CarePlus footprint spans strategically across Ho Chi Minh City including two
15,000 square feet centres in the Tan Binh District and District 7. In 4Q2020, CarePlus opened its third site
which covers 10,000 square feet in Ho Chi Minh City& rsquo s prime District 1. And in Australia, the CHA-SMG
partnership continued to grow its fertility and women& rsquo s health platform.
" We expect this overseas momentum to continue in the year ahead as our strategies for growth gain traction
amid an easing of restrictions and the shift to an endemic phase of tackling the COVID-19 virus in 2022"
Above are for info only. Most of the materials are taken from the company' s annual report.
I am vested.
Below is a quote taken from Message to Shareholders:
" While we are delighted with the results, this is just the beginning as we continue
to chart growth both in Singapore and overseas as we look to emerge stronger from the pandemic."
As seen from above quote, the company is actually very active in Vietnam, Indonesia and Australia.
Indonesia continued to grow " in revenue and profitability despite the challenging COVID-19 environment." .
In Vietnam, the CarePlus footprint spans strategically across Ho Chi Minh City including two
15,000 square feet centres in the Tan Binh District and District 7. In 4Q2020, CarePlus opened its third site
which covers 10,000 square feet in Ho Chi Minh City& rsquo s prime District 1. And in Australia, the CHA-SMG
partnership continued to grow its fertility and women& rsquo s health platform.
" We expect this overseas momentum to continue in the year ahead as our strategies for growth gain traction
amid an easing of restrictions and the shift to an endemic phase of tackling the COVID-19 virus in 2022"
Above are for info only. Most of the materials are taken from the company' s annual report.
I am vested.
Still waiting for the privatisation or takeover. Now that more overseas customers coming in, better businesses and better prospect. Should be a good target.
SMG will appreciate in value. Keep for long term
josephyeo ( Date: 18-Apr-2022 20:11) Posted:
|
Singapore Medical Group
" Our Health segment was also resilient, growing 8.3% yoy to S$62.1 million due to a
combination of organic growth at existing clinics and overall lower patient volume in
FY2020 where non-essential medical services were deferred, and certain clinics were
temporarily closed" .
Above is an extract from Annual Report
Note: SMG revenue/profit are from 3 sectors:
1. Diagnostic n Aesthetics
2. Health sector
3. Others
For info only. Vested!
" Our Health segment was also resilient, growing 8.3% yoy to S$62.1 million due to a
combination of organic growth at existing clinics and overall lower patient volume in
FY2020 where non-essential medical services were deferred, and certain clinics were
temporarily closed" .
Above is an extract from Annual Report
Note: SMG revenue/profit are from 3 sectors:
1. Diagnostic n Aesthetics
2. Health sector
3. Others
For info only. Vested!
Singapore Medical Group
The diagnostic and aesthetics sector is doing well and should be doing even better w the lifting of
covid restrictions which encourage medical tourism.
For info only. Vested!
| Diagnostic and Aesthetics segment, driven by strong domestic demand, grew 29.8% yoy to |
| S$38.4 million. To add further fuel to this growth, we also made the strategic and timely decision |
| to increase the capacity within our diagnostics vertical by 20% in May 2021. |
The diagnostic and aesthetics sector is doing well and should be doing even better w the lifting of
covid restrictions which encourage medical tourism.
For info only. Vested!
Singapore Medical Group
Despite the absence of medical tourism which normally contribute
15% to 20% of annual revenue, the company was able to achieve
all time high in both revenue and profits.
For info only. Vested!
Despite the absence of medical tourism which normally contribute
15% to 20% of annual revenue, the company was able to achieve
all time high in both revenue and profits.
For info only. Vested!